StreetInsider.com News Articles

ME Therapeutics closes $576,500 private placement on CSE

Fri, 17 Jul 2026 09:00:30 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a Vancouver-based biotechnology company, has closed a non-brokered private placement raising $576,500.60.

The financing consisted of 339,118 units priced at $1.70 per unit. Each unit includes one common share and one non-transferable warrant exercisable at $2.00 per share for three years. An acceleration clause allows the company to shorten the warrant expiry with 30 days' notice if the volume-weighted average share price reaches $3.00 for ten consecutive trading days. All shares and warrants are subject to a hold period of four months and one day from issuance.

The company said proceeds will be directed

ME Therapeutics closes $576,500 private placement on CSE

Fri, 17 Jul 2026 09:00:30 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a Vancouver-based biotechnology company, has closed a non-brokered private placement raising $576,500.60.

The company said proceeds will be directed

ME Therapeutics closes $576,500 private placement on CSE

Fri, 17 Jul 2026 09:00:30 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a Vancouver-based biotechnology company, has closed a non-brokered private placement raising $576,500.60.

The company said proceeds will be directed

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”).

Closing of the Financing

The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

Closing of the Financing

The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

Closing of the Financing

The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

Closing of the Financing

The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

Closing of the Financing

The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

Closing of the Financing

The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

Closing of the Financing

The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics Closes Over-Subscribed Private Placement

Fri, 17 Jul 2026 09:00:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

Closing of the Financing

The Financing consisted of the issuance of 339,118 units of the Company (each a “Unit”) at a price of $1.70 per Unit, with

ME Therapeutics announces private placement to raise up to $500,000

Wed, 03 Jun 2026 15:13:18 -0400

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) announced a non-brokered private placement to raise gross proceeds of up to $500,000 through the issuance of up to 294,117 units at $1.70 per unit.

Each unit consists of one common share and one non-transferrable common share purchase warrant. The warrants are exercisable into additional shares at $2.00 each for three years from issuance, subject to an acceleration clause if the volume weighted average share price reaches or exceeds $3.00 for ten consecutive trading days.

The Vancouver-based biotechnology company plans to use proceeds for advancing research and development, evaluating strategic transactions, pursuing a U.S.

ME Therapeutics announces private placement to raise up to $500,000

Wed, 03 Jun 2026 15:13:18 -0400

The Vancouver-based biotechnology company plans to use proceeds for advancing research and development, evaluating strategic transactions, pursuing a U.S.

ME Therapeutics announces private placement to raise up to $500,000

Wed, 03 Jun 2026 15:13:18 -0400

The Vancouver-based biotechnology company plans to use proceeds for advancing research and development, evaluating strategic transactions, pursuing a U.S.

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce a non-brokered private placement to raise gross proceeds of up to $500,000 (the “Offering”) through the issuance of up to 294,117 units (each a “Unit”) at $1.70 per Unit. Each Unit will be comprised of one common share (a “Share’) and one

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

ME Therapeutics Announces Private Placement

Wed, 03 Jun 2026 15:13:00 -0400

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES

ME Therapeutics to Pitch at CSE Capital Tech Connect During Web Summit Vancouver

Thu, 07 May 2026 09:00:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver.

During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity.

Dr. Dhanji

ME Therapeutics to Pitch at CSE Capital Tech Connect During Web Summit Vancouver

Thu, 07 May 2026 09:00:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver.

Dr. Dhanji

ME Therapeutics to Pitch at CSE Capital Tech Connect During Web Summit Vancouver

Thu, 07 May 2026 09:00:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver.

Dr. Dhanji